However, trastuzumab, pertuzumab, and other anti-HER2-targeted drugs have revolutionised the treatment and prognosis of patients with early and advanced HER2-positive breast cancer (Cameron et al., 2017; Early Breast Cancer Trialists' Collaborative g. This evidence concerns the gene ERBB2 and breast cancer.